http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Feb 2026 06:38:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html si-local-file:///var/storage/secattach/20260203/25933883.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html Tue, 03 Feb 2026 06:38:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html si-local-file:///var/storage/secattach/20260203/25933883.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html Tue, 03 Feb 2026 06:38:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html si-local-file:///var/storage/secattach/20260203/25933883.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+03/25933883.html Tue, 03 Feb 2026 06:38:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html si-local-file:///var/storage/secattach/20260202/25927145.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html Mon, 02 Feb 2026 07:21:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html si-local-file:///var/storage/secattach/20260202/25927145.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html Mon, 02 Feb 2026 07:21:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html si-local-file:///var/storage/secattach/20260202/25927145.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Feb+01/25927145.html Mon, 02 Feb 2026 07:21:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html si-local-file:///var/storage/secattach/20260108/25822680.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html Thu, 08 Jan 2026 06:30:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html si-local-file:///var/storage/secattach/20260108/25822680.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html Thu, 08 Jan 2026 06:30:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html si-local-file:///var/storage/secattach/20260108/25822680.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jan+08/25822680.html Thu, 08 Jan 2026 06:30:00 -0500 O.00551852 PHAR PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Press+Releases/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html <p align="justify"><b>Leiden, The Netherlands, January 8, 2026: </b>Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full year 2025 and plans to host a virtual Investor Day on February 3, 2026, at 10:00 am EST (16:00 CET).</p> <p align="justify">Total 2025 revenues are estimated to be approximately US$376 million*, exceeding the upwardly revised guidance range of US$365 to US$375 million provided in November 2025 and representing approximately 27% growth versus 2024. This strong performance reflects continued growth of RUCONEST® and rising demand for Joenja®, driven primarily by patient uptake in the http://www.streetinsider.com/Globe+Newswire/Pharming+Group+reports+preliminary+2025+revenues+and+announces+Investor+Day/25821844.html Thu, 08 Jan 2026 01:00:00 -0500 A.01019570 A.05637112 A.35954321 A.40221050 O.00551852 O.00917591 O.20042365 O.20737027 O.22115017 PHAR PHARM PHARM